ATC Group: V09AX05 Florbetapir (18F)

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V09AX05 in the ATC hierarchy

Level Code Title
1 V Various
2 V09 Diagnostic radiopharmaceuticals
3 V09A Central nervous system
4 V09AX Other central nervous system diagnostic radiopharmaceuticals
5 V09AX05

Active ingredients in V09AX05

Active Ingredient Description
Florbetapir ¹⁸F

Florbetapir ¹⁸F binds to β-amyloid plaques and the ¹⁸F isotope produces a positron signal that is detected by a PET scanner. Florbetapir ¹⁸F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Related product monographs

Title Information Source Document Type  
AMYVID Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Estonia (EE)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.